



Program

"ALS & MOTOR NEURON DISEASES: WHAT AVENUES FOR THE FUTURE?"

17TH MARCH 2022

AT THE PARISANTÉ CAMPUS
HYBRID EVENT

Conference
organised on the
initiative of

france
biotech

biotech | medtech | e-santé | IA
LES ENTREPRENEURS DE LA HEALTHTECH

Our partners (subject to update)



THE CONTEXT

Presentation

Today in France, there is a real desire to accelerate research and the provision of therapeutic solutions for patients suffering from ALS and motor neurone diseases. Complex and high-risk pathologies, patients and their families are waiting for innovations.

The objective to which professionals must respond is to facilitate and promote the conversion of rich and efficient fundamental research on the subject, both at French and European level, into effective treatments for the disease.

The symposium **"ALS and motor neurone diseases: what avenues for the future?"** organised at the initiative of France Biotech, in partnership with numerous players in the sector, **aims to take stock of current research and to collectively define an action plan to identify avenues for the future, at the level of European cooperation involving the leading experts and entrepreneurs involved in health innovation.**

The aim of this conference is to facilitate the conversion of rich and successful basic research (at French and European level) into effective treatments for the disease, enabling the provision of therapeutic solutions for ALS patients.

This conference will help to :

- Create bridges and links to facilitate networking and exchanges between different ALS stakeholders
- Identify, encourage and promote promising therapeutic projects
- Collectively propose courses of action to remove obstacles and reduce risks
- To respond to the need for acculturation between the players in the field

The event will take place in English and will be held in a hybrid format at the PariSanté campus. It will present an opportunity to meet with all the scientific, academic, research, patient and entrepreneurial actors involved in the subject.

THE ACTORS

Organizers and partners

France Biotech
Act4 ALS-MND
AFMTéléthon
ARSLA
FILSLAN
Orphan Dev
Association TECS
Les p'tites mains de Charcot

Steering committee

Pr Olivier Blin (Orphan Dev)
Amandine Bordet (ICM)
Jean-François Briand (AFM-Téléthon)
Dr Gaelle Bruneteau (Filière FILSAN et réseau ACT4ALS-MND, ICM Paris)
Julie Catteau (Filière FILSLAN)
Olivier Chabanon (France Biotech)
Florence Cocqueel (OrphanDev)
Pr Philippe Couratier (Filière FILSLAN)
Virginie Delmas (Tous en selle contre la SLA)
Pr Claude Desnuelle (Association ARSLA)
Valérie Meyer-Sagnier (Aidante)
Constance Montazel (France Biotech)
Franck Mouthon (France Biotech)
David Sagnier (Patient)
Julien Veys (Theranexus)

Co-organizers



Emcee of ceremony: Fabrice Papillon

2:00 pm - 2:05 pm - Opening

Speaker :

- Franck Mouthon (President of France Biotech)

2:05 pm - 3:05 pm - Keynote : state of the art on ALS

Speakers :

- Jean-François Briand (AFM Téléthon)
- Pr Philippe Couratier (Filière FILSLAN)
- Dr Merit Cudkowicz (Massachusetts General Hospital)
- Pr Claude Desnuelle (Association ARSLA)
- Luc Dupuis (Université de Strasbourg, USIAS)

3:05 pm - 4:05 pm - Round table 1 : "Securing and strengthening investment"

Moderator : Julien Veys (Theranexus)

Speakers :

- Secrétariat Général Pour l'Investissement - **tbc**
- Laurence Bressac (Encefa)
- Jean-François Briand (AFM Téléthon)
- Philippe Guédât (InflectisBiosciences)
- Joel Zhizhong (Sofinnova)

4:05 pm - 4:25 pm - Break

4:25 pm - 5:25 pm - Round table 2 : "Accelerating research: bench, diagnosis and clinical trials"

Moderator : Dr Angela Genge (McGill - Montréal)

Speakers :

- Olivier Blin (Orphan Dev)
- Dr Gaëlle Bruneteau (Filière FILSAN et réseau ACT4ALS-NMD, ICM Paris)
- Joel Doré (INRAE)
- Luc Dupuis (Université de Strasbourg)
- Pr Pamela Shaw (Université de Sheffield)
- Piera Smeriglio (Institut de Myologie, INSERM - Paris) - **tbc**

5:25 pm - 6:25 pm - Round table 3 : "Better measurement of patient benefits and encouraging"

Moderator : Hervé Nabarette (AFM Téléthon)

Speakers :

- Agence Nationale de Sécurité du Médicament - **tbc**
- Pr Pierre Cochat (Haute Autorité de Santé)
- Pr Claude Desnuelle (Association ARSLA)
- Valérie Meyer-Sagnier (Aidante)
- Catherine Raynaud (Leem)
- David Sagnier (Patient)

6:25 pm - 6:40 pm - Conclusion

Speakers :

- French representative at the European Commission - **tbc**
- Pr Philippe Berta (French Deputy)

6:40 pm - 8:00 pm - BtoB meeting

CONTACTS ORGANIZATION AND PRACTICAL INFORMATION

Scientific organization

Olivier CHABANON

General Delegate

T : +33 (0)1 88 33 46 80 – M : +33 (0)6 64 07 89 74

Email : olivier.chabanon@france-biotech.org

Constance MONTAZEL

Institutional Relations & Public Affairs Officer

T : +33 (0)1 88 32 11 60 – M : +33 (0)7 61 10 65 32

Email : constance.montazel@france-biotech.org

Practical organization and communication

Alice MOUILLADE

Communication Officer

Email : communication@france-biotech.org

france
biotech

biotech | medtech | e-santé | IA

LES ENTREPRENEURS DE LA HEALTHTECH